Tirzepatide, sold under the brand names Mounjaro for type 2 diabetes and Zepbound for chronic weight management, is one of the most-discussed peptide drugs of the past several years, and one of the most thoroughly studied.
What It Is
Tirzepatide is a synthetic peptide that acts as a dual agonist, meaning it activates two separate hormone receptors: GLP-1 (glucagon-like peptide-1) and GIP (glucose-dependent insulinotropic polypeptide). Both are naturally occurring gut hormones released after eating that influence insulin secretion, appetite, and digestion. Tirzepatide is engineered to mimic both simultaneously and to resist rapid breakdown, allowing once-weekly injection.
Regulatory Status
Tirzepatide is FDA-approved, first for type 2 diabetes in 2022 (as Mounjaro), then for chronic weight management in 2023 (as Zepbound). It went through the full clinical trial and regulatory review process described elsewhere on this site, including large Phase 3 trials before approval.
What the Research Shows
The SURPASS trial program established its effects on blood sugar control in type 2 diabetes, while the SURMOUNT trial program evaluated it for weight management, reporting substantial average weight loss among participants over roughly 72 weeks, generally exceeding what earlier single-receptor GLP-1 drugs achieved in comparable trials. As with any drug, individual results in trials varied considerably, and real-world outcomes depend on adherence, dose, and individual physiology.
Common Side Effects
Gastrointestinal side effects, nausea, diarrhea, constipation, and vomiting, are the most commonly reported, particularly during dose escalation, and are the leading reason patients discontinue treatment in trials. Like other drugs in this class, it carries a boxed warning regarding thyroid C-cell tumors observed in rodent studies and is contraindicated for people with a personal or family history of medullary thyroid carcinoma or MEN 2.
The Bottom Line
Tirzepatide represents one of the most rigorously tested peptide drugs available, with a large trial base behind both its approved indications. That doesn't eliminate side effects or make it appropriate for everyone, but it does mean decisions about using it can be grounded in substantial published clinical evidence rather than anecdote, which isn't true of most peptides covered on this site.
How It Compares Within Its Class
Tirzepatide is often discussed alongside semaglutide as the two leading options in this drug class, and the two are compared directly in this site's dedicated comparison guide. Both share the core GLP-1 mechanism, but tirzepatide's added GIP activity is the main biological distinction driving most of the efficacy comparisons between them in current research.
Dosing and Administration in Practice
Tirzepatide is titrated gradually, typically starting at 2.5 mg weekly and increasing in defined steps over several months up to a maintenance dose, a schedule specifically designed around the trial data showing that faster escalation increases gastrointestinal side effects without improving long-term outcomes. It's delivered via a pre-filled pen for subcutaneous injection, generally in the abdomen, thigh, or upper arm, with site rotation recommended for the same reasons discussed in this site's injection safety guide.